A Prospective, Single Arm Study of Nimotuzumab Combined With NALIRIFOX in the Treatment of Locally Advanced Pancreatic Cancer

NCT06429904 Phase 2 ACTIVE_NOT_RECRUITING

This is a prospective, open-label, single arm clinical study. The main purpose of the study is to evaluate the clinical efficacy and safety of Nimotuzumab combined with NALIRIFOX in the treatment of locally advanced pancreatic cancer (LAPC).

Details

Lead sponsor	Peking Union Medical College Hospital
Phase	Phase 2
Status	ACTIVE_NOT_RECRUITING
Enrolment	31
Start date	2024-05-15
Completion	2027-05

Conditions

• Locally Advanced Pancreatic Cancer

Interventions

• Nimotuzumab+ NALIRIFOX

Primary outcomes

• overall survival (OS) — Up to 24 months
  The time from the beginning of treatment to death due to any cause.

Countries

China